1623 Capital’s Zymeworks ZYME Stock Holding History

1623 Capital’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,724	Closed	-$224K	–	77
2021 Q3	$224K	Buy	+7,724	New	+$257K	0.09%	70
2021 Q2	–	Sell	-2,346	Closed	-$74K	–	91
2021 Q1	$74K	Buy	+2,346	New	+$95.3K	0.03%	76

Other funds holding ZYME

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

1623 Capital's ZYME Position: Q4 2021 in Review

1623 Capital sold out of Zymeworks (ZYME) in Q4 2021, closing a stake of 7,724 shares — an estimated $224K sold.

1623 Capital first reported a position in ZYME in Q1 2021 and held it in 2 quarters. The position peaked at $224K in Q3 2021. 114 funds tracked by Wall St. Rank hold ZYME as of Q4 2021.

1623 Capital reported no remaining Zymeworks position as of Q4 2021 after selling out during the quarter.
1623 Capital sold 7,724 Zymeworks shares in Q4 2021, an estimated $224K.
1623 Capital first reported a position in Zymeworks in Q1 2021 and held it in 2 quarters.
1623 Capital's Zymeworks position peaked at $224K in Q3 2021.
114 funds tracked by Wall St. Rank held Zymeworks as of Q4 2021.

Based on 1623 Capital's 13F filing for Q4 2021, filed 11 Feb 2022.